nach oben

Erschienen in:

23.03.2018 | Photodynamische Therapie | Leitlinien, Stellungnahmen und Empfehlungen

Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS)

Stand Januar 2018

verfasst von: Berufsverband der Augenärzte Deutschlands e. V. (BVA), Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft e. V. (RG)

Erschienen in: Die Ophthalmologie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Auszug

Die Chorioretinopathia centralis serosa (CCS) ist eine ein- oder beidseitig auftretende Erkrankung der Makula, die mit einer Ansammlung von subretinaler Flüssigkeit einhergeht.

…

Nur mit Berechtigung zugänglich

Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT (2013) Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2:96–101PubMedPubMedCentral

Ayata A, Tatlipinar S, Kar T, Unal M, Ersanli D, Bilge AH (2009) Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 93:79–82CrossRefPubMed

Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152:784–792.e2CrossRefPubMed

Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237CrossRefPubMed

Bonini Filho MA, de Carlo TE, Ferrara D, Adhi M, Baumal CR, Witkin AJ, Reichel E, Duker JS, Waheed NK (2015) Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133:899–906CrossRefPubMed

Bousquet E, Beydoun T, Rothschild P‑R, Bergin C, Zhao M, Batista R, Brandely M‑L, Couraud B, Farman N, Gaudric A et al (2015) Spironolactone for nonresolving central serous chorioretinopathy. Retina 35:2505–2515CrossRefPubMedPubMedCentral

Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A (2017) Optical coherence tomography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina. https://doi.org/10.1097/IAE.0000000000001580

Bujarborua D (2001) Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 79:417–421CrossRefPubMed

Bujarborua D, Chatterjee S, Choudhury A, Bori G, Sarma AK (2005) Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina 25:422–429CrossRefPubMed

10.

Bujarborua D, Nagpal PN, Deka M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339–351CrossRefPubMed

11.

Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F (2010) Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 4:899–903CrossRefPubMedPubMedCentral

12.

Chan W‑M, Lam DSC, Lai TYY, Tam BSM, Liu DTL, Chan CKM (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458CrossRefPubMedPubMedCentral

13.

Chan W‑M, Lai TYY, Lai RYK, Liu DTL, Lam DSC (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765CrossRefPubMed

14.

Cheng C‑K, Chang C‑K, Peng C‑H (2017) Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 37:325–333CrossRefPubMed

15.

Chong C‑F, Yang D, Pham TQ, Liu H (2012) A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep. https://doi.org/10.1136/bcr-2012-006970 PubMedPubMedCentral

16.

Chuang EL, Sharp DM, Fitzke FW, Kemp CM, Holden AL, Bird AC (1987) Retinal dysfunction in central serous retinopathy. Eye (Lond) 1(Pt 1):120–125CrossRef

17.

Chung Y‑R, Seo EJ, Lew HM, Lee KH (2013) Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye 27:1339–1346CrossRefPubMedPubMedCentral

18.

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82. https://doi.org/10.1016/j.preteyeres.2015.05.003 CrossRefPubMed

19.

Daruich A, Matet A, Marchionno L, De Azevedo J‑D, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37(10):1905. https://doi.org/10.1097/IAE.0000000000001443 CrossRefPubMedPubMedCentral

20.

Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ (1995) In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 36:718–729PubMed

21.

Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR (2003) Central serous chorioretinopathy in African Americans. J Natl Med Assoc 95:553–559PubMedPubMedCentral

22.

Elsner H, Pörksen E, Klatt C, Bunse A, Theisen-Kunde D, Brinkmann R, Birngruber R, Laqua H, Roider J (2006) Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 244(12):1638–1645CrossRefPubMed

23.

Ficker L, Vafidis G, While A, Leaver P (1988) Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 72:829–834CrossRefPubMedPubMedCentral

24.

Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB (2011) Finasteride for chronic central serous chorioretinopathy. Retina 31:766–771CrossRefPubMedPubMedCentral

25.

French DD, Margo CE (2010) Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 30:271–274CrossRefPubMed

26.

Gäckle HC, Lang GE, Freissler KA, Lang GK (1998) Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects. Ophthalmologe 95(8):529–533CrossRefPubMed

27.

de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650–656PubMed

28.

Gass JD, Little H (1995) Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 102:737–747CrossRefPubMed

29.

Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820CrossRefPubMedPubMedCentral

30.

Haimovici R, Rumelt S, Melby J (2003) Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110:698–703CrossRefPubMed

31.

Heinrich MR (1974) Central serous retinopathy and alpha-blockaders. Bull Soc Ophtalmol Fr 74:681–683PubMed

32.

Iacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol 253:1889–1897CrossRefPubMed

33.

Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S (2003) Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 23:1–7 (quiz 137-8)CrossRefPubMed

34.

Jain AK, Kaines A, Schwartz S (2010) Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 248:1037–1039CrossRefPubMed

35.

de Jong EK, Breukink MB, Schellevis RL, Bakker B, Mohr JK, Fauser S, Keunen JEE, Hoyng CB, den Hollander AI, Boon CJF (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562–570CrossRefPubMed

36.

Katsimpris JM, Pournaras CJ, Sehgelmeble CW, Petropoulos IK (2007) Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch Clin Exp Ophthalmol 245:460–463CrossRefPubMed

37.

Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A (2003) Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 87:709–712CrossRefPubMedPubMedCentral

38.

Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115:169–173CrossRefPubMed

39.

Klatt C, Saeger M, Oppermann T, Pörksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J (2011) Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 95:83–88CrossRefPubMed

40.

Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, Staines H, Hykin PG, MINERVA study group (2017) Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. https://doi.org/10.1097/IAE.0000000000001744

41.

Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C (2015) Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol 200:25–29CrossRefPubMed

42.

Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, Palanker D (2014) Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 34:87–97CrossRefPubMed

43.

Leaver P, Williams C (1979) Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 63:674–677CrossRefPubMedPubMedCentral

44.

Lee H, Lee J, Chung H, Kim HC (2016) Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina 36:1372–1380CrossRefPubMed

45.

Lim JI, Spee C, Hinton DR (2010) A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 30:1472–1478CrossRefPubMedPubMedCentral

46.

Lipowski ZJ, Kiriakos RZ (1971) Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics 12:398–401CrossRefPubMed

47.

Liu B, Deng T, Zhang J (2016) Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 36:9–19CrossRefPubMed

48.

Ma J, Meng N, Xu X, Zhou F, Qu Y (2014) System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 92:e594–e601CrossRefPubMed

49.

Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117:1792–1799CrossRefPubMed

50.

Matet A, Daruich A, Zola M, Behar-Cohen F (2017) Risk factors for recurrences of central serous chorioretinopathy. Retina. https://doi.org/10.1097/IAE.0000000000001729

51.

Matsumoto H, Kishi S, Otani T, Sato T (2008) Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 145:162–168CrossRefPubMed

52.

Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA (2007) Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27:943–946CrossRefPubMed

53.

Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126CrossRefPubMedPubMedCentral

54.

Nicholson BP, Atchison E, Idris AA, Bakri SJ (2017) Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol 63(1):1–8. https://doi.org/10.1016/j.survophthal.2017.06.008 CrossRefPubMed

55.

Nicolò M, Zoli D, Musolino M, Traverso CE (2012) Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 153:474–480.e1CrossRefPubMed

56.

Nielsen JS, Jampol LM (2011) Oral mifepristone for chronic central serous chorioretinopathy. Retina 31:1928–1936CrossRefPubMed

57.

O’Keefe JH, Abuissa H, Pitt B (2008) Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 10:492–497CrossRefPubMed

58.

Peiretti E, Ferrara DC, Caminiti G, Mura M, Hughes J (2015) Choroidal neovascularization in caucasian patients with longstanding central serous chorioretinopathy. Retina 35:1360–1367CrossRefPubMed

59.

Piccolino FC, De La Longrais RR, Manea M, Cicinelli S (2008) Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina 28:1008–1012CrossRefPubMed

60.

Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P, Central Serous Chorioretinopathy Study Group (2016) Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 37(5):1115. https://doi.org/10.1007/s10792-016-0377-2 CrossRef

61.

Pikkel J, Beiran I, Ophir A, Miller B (2002) Acetazolamide for central serous retinopathy. Ophthalmology 109:1723–1725CrossRefPubMed

62.

Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, Investigators EPHESUS (2008) Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118:1643–1650CrossRefPubMed

63.

Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM (2015) Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol 160:581–587.e1CrossRefPubMed

64.

Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A (2011) The effect of helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 17:99–103PubMedPubMedCentral

65.

Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ et al (2017) A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior). Retina. https://doi.org/10.1097/IAE.0000000000001649 PubMed

66.

Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F et al (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 149:307–315.e2CrossRefPubMed

67.

Robertson DM, Ilstrup D (1983) Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 95:457–466CrossRefPubMed

68.

Roider J, Brinkmann R, Wirbelauer C, Laqua H, Birngruber R (2000) Subthreshold (RPE) photocoagulation in macular diseases – a pilot study. Br J Ophthalmol 84:40–47CrossRefPubMedPubMedCentral

69.

Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P (2015) Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011841.pub2 PubMedPubMedCentral

70.

Scholz P, Altay L, Fauser S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34:1528–1555CrossRefPubMedPubMedCentral

71.

Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, Merriam JC, Barbazetto I, Slakter JS, Chang S et al (2014) Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 35:859–867CrossRefPubMedPubMedCentral

72.

Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, Shulman S, Guzner-Gur H, Loewenstein A, Goldstein M (2017) Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol 95(7):e610. https://doi.org/10.1111/aos.13491 CrossRefPubMed

73.

Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O (2011) Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 151:303–309.e1CrossRefPubMed

74.

Sharma T, Shah N, Rao M, Gopal L, Shanmugam MP, Gopalakrishnan M, Bhende P, Bhende M, Shetty NS, Baluswamy S (2004) Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 111:1708–1714CrossRefPubMed

75.

Shin MC, Lim JW (2011) Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 31:1937–1943CrossRefPubMed

76.

Shinojima A, Hirose T, Mori R, Kawamura A, Yuzawa M (2010) Morphologic findings in acute central serous chorioretinopathy using spectral domain-optical coherence tomography with simultaneous angiography. Retina 30:193–202CrossRefPubMed

77.

Shinojima A, Sawa M, Sekiryu T, Oshima Y, Mori R, Hara C, Sugano Y, Kato A, Asato H, Yuzawa M et al (2017) A Multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. Ophthalmologica 237:159–166. https://doi.org/10.1159/000455807 CrossRefPubMed

78.

Shulman S, Goldenberg D, Schwartz R, Habot-Wilner Z, Barak A, Ehrlich N, Loewenstein A, Goldstein M (2016) Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 254:15–22CrossRefPubMed

79.

Spaide RF, Klancnik JM (2005) Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 112:825–833CrossRefPubMed

80.

Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996a) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103(2080):2070–2079CrossRefPubMed

81.

Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996b) Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16:203–213CrossRefPubMed

82.

Spitznas M (1986) Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 224:321–324CrossRefPubMed

83.

Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, Sen E, Ozdal P, Ozturk F (2014) Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int J Ophthalmol 7:350–354PubMedPubMedCentral

84.

Tseng CC, Chen SN. (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99(8):1070–1077. https://doi.org/10.1136/bjophthalmol-2014-305353

85.

Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, de Abreu JF, Cachulo ML, Silva R (2013) Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 251(7):1697–1705. https://doi.org/10.1007/s00417-013-2270-2

86.

Verma L, Sinha R, Venkatesh P, Tewari H (2004) Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: A pilot, randomized controlled trial [ISRCTN84128484. BMC Ophthalmol 4:15CrossRefPubMedPubMedCentral

87.

Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF (2000) Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 238:76–80CrossRefPubMed

88.

Wong R, Chopdar A, Brown M (2004) Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy. Eye 18:262–268CrossRefPubMed

89.

Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV (2017) Nondamaging retinal laser theray for treatment of central serous chorioretinopathy: what is the evidence? Retina 37:1021–1033CrossRefPubMed

90.

Wu ZHY, Lai RYK, Yip YWY, Chan WM, Lam DSC, Lai TYY (2011) Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 31:1378–1386CrossRefPubMed

91.

Yalcinbayir O, Gelisken O, Akova-Budak B, Ozkaya G, Gorkem Cevik S, Yucel AA (2014) Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina 34:705–712CrossRefPubMed

92.

Yannuzzi LA (1986) Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 84:799–845PubMedPubMedCentral

93.

Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA (1984) Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 91:1554–1572CrossRefPubMed

Titel: Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS)
Stand Januar 2018
verfasst von: Berufsverband der Augenärzte Deutschlands e. V. (BVA)
Deutsche Ophthalmologische Gesellschaft (DOG)
Retinologische Gesellschaft e. V. (RG)
Publikationsdatum: 23.03.2018
Verlag: Springer Medizin
Schlagwörter: Photodynamische Therapie
Eplerenon
Erschienen in: Die Ophthalmologie / Ausgabe 5/2018
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-018-0680-6

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Diagnostik des trockenen Auges

Häufigkeit der Brillenträger in Deutschland

Kinderaugenheilkunde

Suprachoroidale minimalinvasive Glaukomchirurgie

Analyse der Brillenstärken zeigt keine Zunahme der Myopie in Deutschland von 2000 bis 2015

Frühzeitiges Auftreten eines Fingolimod-assoziierten Makulaödems

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde